

# Hepatitis C Enrollment Form

## Medications A-E

(Eplclusa®)



Fax Referral To: 1-877-552-2907

Email Referral To: customerservicefax@caremark.com

Phone: 1-888-345-1678

### Six Simple Steps to Submitting a Referral

#### 1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: \_\_\_\_\_ Address: \_\_\_\_\_ City, State, ZIP: \_\_\_\_\_  
Preferred Contact Methods:  Phone (to primary # provided below)  Text (to cell # provided below)  Email (to email provided below)  
*Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.*  
Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender:  Male  Female  
Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_

#### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_  
Address: \_\_\_\_\_ City, State, ZIP: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

#### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

#### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Ship to:  Patient  Office  Other: \_\_\_\_\_

##### Diagnosis (ICD-10):

- B17.10 Acute Hepatitis C without hepatic coma  B17.11 Acute Hepatitis C with hepatic coma  
 B18.2 Chronic Hepatitis C  B19.20 Unspecified Viral Hepatitis C without hepatic coma  
 B20 HIV  Other Code: \_\_\_\_\_ Description: \_\_\_\_\_

For additional ICD-10 information, please visit [CVS Specialty Healthcare Professionals Website](https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us)

<https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us>

##### Patient Clinical Information:

Allergies: \_\_\_\_\_ Weight: \_\_\_\_\_ lb/kg Height: \_\_\_\_\_ in/cm  
HCV Genotype:  1a  1b  1  2  3  4  5  6 AND  No Cirrhosis  Compensated Cirrhosis  Decompensated Cirrhosis  
Is patient:  Naïve  Partial Responder  Non-Responder  Relapser; Last Date of Therapy: \_\_\_\_\_ Product Name(s): \_\_\_\_\_  
Is patient currently on Hepatitis C Virus therapy?  No  Yes, Therapy Start Date: \_\_\_\_\_ Product Name(s): \_\_\_\_\_  
Is patient post-liver transplant?  Yes  No For Zepatier™ genotype 1a patients, NS5A polymorphism present?  Yes  No

##### Nursing:

Specialty pharmacy to coordinate injection training/home health nurse visit as necessary?  Yes  No  
Site of Care:  MD office  Infusion Clinic  Outpatient Health  Home Health  
Injection training not necessary. Date training occurred: \_\_\_\_\_  
Reason:  MD office training patient  Pt already independent  Referred by MD to alternate trainer

#### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Eplclusa (sofosbuvir / velpatasvir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir	Take one tablet once daily.	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

#### 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X \_\_\_\_\_ X \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2020 CVS Specialty and/or one of its affiliates. 75-38495B 11032020

# Medications F-V Hepatitis C Enrollment Form

(Harvoni®, Ledipasvir/Sofosbuvir, Mavyret™, Pegasys®, Pegintron®, Ribavirin, Ribasphere®, Sofosbuvir/Velpatasvir, Sovaldi®, Technivie™, Viekira Pak™)

## Please complete Patient and Prescriber information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Harvoni (ledipasvir/ sofosbuvir)	Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	Take PO once daily with or without food. Do not take within 4 hours of antacids.	Quantity: 28-day supply Refills: <input type="checkbox"/> 8 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> 24 weeks
<input type="checkbox"/> Ledipasvir/ Sofosbuvir	Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	Take PO once daily with or without food.	Quantity: 28-day supply Refills: <input type="checkbox"/> 8 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> 24 weeks
<input type="checkbox"/> Mavyret (glecaprevir and pibrentasvir)	Fixed-dose combination tablet of 100mg glecaprevir and 40mg pibrentasvir	Take three tablets PO once a day with food.	Quantity: 28-day supply Refills: <input type="checkbox"/> 8 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> Other _____
<input type="checkbox"/> Pegasys (peginterferon alfa-2a)	<input type="checkbox"/> 180 mcg / 0.5 mL ProClick™ Autoinjector <input type="checkbox"/> Other: _____	<input type="checkbox"/> Inject 180 mcg SC once a week as directed. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Pegintron (peginterferon alfa-2b)	<input type="checkbox"/> 120 mcg REDIPEN® <input type="checkbox"/> 150 mcg REDIPEN <input type="checkbox"/> Other: _____	<input type="checkbox"/> Inject _____ mcg SC weekly. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Ribavirin	<input type="checkbox"/> 200 mg tablets <input type="checkbox"/> 200 mg capsules	Take _____ tabs/caps PO q am and _____ tabs/caps q pm for a total of _____ mg daily with food.	Quantity: _____ Refills: _____
<input type="checkbox"/> Ribasphere RibaPak® (ribavirin)	<input type="checkbox"/> 600 / 600 mg <input type="checkbox"/> 600 / 400 mg <input type="checkbox"/> 400 / 400 mg <input type="checkbox"/> 200 / 400 mg	Take _____ mg PO q am and _____ mg q pm for a total of _____ mg daily with food.	Quantity: _____ Refills: _____
<input type="checkbox"/> Sofosbuvir / Velpatasvir	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir	Take one tablet once daily.	Quantity: _____ Refills: _____
<input type="checkbox"/> Sovaldi (sofosbuvir)	<input type="checkbox"/> 400 mg tablets	Take one 400 mg tablet PO once a day.	Quantity: 28-day supply Refills: _____
<input type="checkbox"/> Technivie (ombitasvir/paritaprevir/rit onavir)	Fixed dose combination tablet of ombitasvir / paritaprevir / ritonavir 12.5 mg / 75 mg / 50 mg	Take two tablets once daily in the morning.	Quantity: 28-day supply Refills: 12 weeks
<input type="checkbox"/> Viekira Pak (ombitasvir/paritaprevir/rit onavir tabs and dasabuvir tabs)	Copackaged ombitasvir / paritaprevir / ritonavir 12.5 mg / 75 mg / 50 mg and dasabuvir 250 mg	Take 2 pink tablets (ombitasvir, paritaprevir, ritonavir) once daily (morning) and 1 beige tablet (dasabuvir) twice daily (morning and evening) with meals.	Quantity: 28-day supply Refills: <input type="checkbox"/> 12 weeks <input type="checkbox"/> 24 weeks

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X \_\_\_\_\_

X \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2020 CVS Specialty and/or one of its affiliates. 75-38495B 11032020

# Medications V-Z

## Hepatitis C Enrollment Form

(Vosevi™, Zepatier)

**Please complete Patient and Prescriber information**

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

**5 PRESCRIPTION INFORMATION**

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir/100 mg voxilaprevir	Take one tablet PO once a day with food.	Quantity: 28-day supply Refills: <input type="checkbox"/> 12 weeks <input type="checkbox"/> Other _____
<input type="checkbox"/> Zepatier (elbasvir/grazoprevir)	Fixed dose combination tablet of 50 mg elbasvir / 100 mg grazoprevir	Take one tablet once daily with or without food.	Quantity: 28-day supply Refills: <input type="checkbox"/> 12 weeks <input type="checkbox"/> 16 weeks

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

**6 PHYSICIAN SIGNATURE REQUIRED**

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

**X** \_\_\_\_\_ **X** \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2020 CVS Specialty and/or one of its affiliates. 75-38495B 11032020